Catalyst Wire Dossier Catalyst Wire Dossier

CLE-100 (oral esketamine)

esketamine · Clexio Biosciences Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CLE-100 (oral esketamine), covering 2026-03-19 to 2026-03-19. Get the full timeline:

Most recent: Clinical Trial Update: A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder [Phase 2]

See pricing